The questions in this section may arise when speaking with parents and caregivers about respiratory syncytial virus (RSV), Synagis, and Cradle with Care℠.
Like the flu, RSV is a seasonal virus. The duration of the RSV season varies depending on the location and year, but it usually starts in the fall and continues into the spring. In some parts of the country, the length of the RSV season may be different.1 You may obtain RSV surveillance reports directly from the RSVAlert® website at www.rsvalert.com. You may also call 1-877-633-4411.
Most children with RSV disease suffer mild to moderate cold-like symptoms. For some high-risk babies, RSV disease can be more severe. Premature infants born at ≤35 weeks gestational age and children ≤24 months of age with certain heart or lung conditions are at high risk for developing a serious lung infection, such as bronchiolitis and/or pneumonia.2,3
Like the flu, RSV can be spread by sneezing and coughing or by physical contact, such as touching or shaking hands. RSV can live up to 5 hours on countertops and other surfaces and spreads very quickly in daycare centers and crowded households.4 RSV infects nearly all children by their
Signs and symptoms of severe RSV disease include4:
Synagis is a prescription medication that is used to help prevent a serious lung disease caused by RSV in infants born prematurely (≤35 weeks gestational age) or children ≤24 months of age who have certain types of heart or lung problems.2
No. Though not a vaccine, Synagis is an FDA-approved prescription injection of antibodies that is given monthly to help protect high-risk children from severe RSV disease throughout the RSV season. Each dose provides protection for about 28–30 days.2
Possible serious side effects include severe allergic reactions, which may occur after any dose of Synagis. Such reactions may be life threatening or cause death. Unusual bruising and/or groups of tiny red spots on the skin have also been reported. Common side effects of Synagis include fever and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort).2
To report a suspected adverse reaction or receive additional medical information,
call AstraZeneca at 1-877-633-4411.
If your high-risk baby is on Synagis, he or she will need 1 shot each month during RSV season. Your high-risk baby needs to keep getting Synagis as long as prescribed by your baby’s doctor. Talk to your doctor about what is right for your child.
Yes. No matter how healthy your baby looks, a prescription for Synagis means he or she is at high risk for severe RSV disease. Remember, your high-risk baby may need help with protection from RSV. Your doctor will tell you when RSV season has ended and your high-risk baby can stop monthly Synagis shots.
Most high-risk babies won’t need Synagis for a second RSV season, but some babies are still at high risk for severe RSV disease in their second year and may need Synagis for more than 1 RSV season. Ask your doctor if your baby will need Synagis for a second season.
While many health plans cover Synagis, the levels of coverage and the requirements for getting it can vary. If a patient is without prescription coverage or can’t afford their medication, AstraZeneca may be able to help. For more information, please call Access 360™ at 1-844-ASK-A360.
Cradle with Care promotes compliance with recommended therapy through appointment reminders, provides access to education about RSV, and offers information about financial support.
There are 2 ways to sign up:
All enrollment materials are also available in Spanish. Parents/caregivers must sign the Spanish version of the opt-in page so they receive communications in Spanish.
Parents/caregivers do not have to enroll to receive Synagis; however, they will need to enroll in Cradle with Care in order to receive doctor visit reminders and other helpful tools offered by the program. Their doctor can still provide them with appointment reminders and other educational material even if they don't sign up for the Cradle with Care program.
The appointment reminders are designed to promote compliance with recommended therapy. Parents/caregivers are instructed to talk to their doctor to schedule appointments.
Yes, parents/caregivers can change their mind at any time and opt out of Cradle with Care. There are 3 ways
to opt out: through the unsubscribe link located at the top and bottom of each email, through the return mailing address provided in all materials sent through the mail, or by calling the AstraZeneca Information line at
Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.
The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.
Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or
Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.